Circulating SESN2 levels have been identified viable in indicating disease severity or prognosis, including cardiovascular diseases [117–119], respiratory diseases [120, 121], neurodegenerative diseases [122, 123], metabolic diseases [124, 125], cancers [106, 126], etc. Since SESN2 expression is dynamically changed during liver pathology, we hypothesize that SESN2 has a good potential as a clinical biomarker and prognostic indicator for liver diseases. This evidence concerns the gene SESN2 and neurodegenerative disease.